[quote]Alpha F wrote:
[quote]buffd_samurai wrote:
I, unfortunately, do not tolerate aniracetam very well. Seriously speaking, it puts me in a SERIOUSLY bad mood. It basically turns me into a “bad drunk”, i.e. someone who is overly aggressive and “throws their weight around” when under its “influence”. Why this is, I don’t know. But it looks like fat soluable racetams are definitely not for me.
Anyone else like this? [/quote] Yes.[quote]
Anyone had a reasonable rationale mechanism that might explain such strange reactions for me?[/quote]
You could be dopamine dominant in your genetic brain make up.
By taking a substance that might enhance dopamine levels in you pre frontal cortex you tip over an already high dopamine level. Two of the functions implicated on the pre frontal cortex are: personality expression and moderation of correct social behavior. If you are, by default, high dopamine, low serotonin and low norepinepherine, enhancing dopamine and serotonin might explain the neurological effect on your mood and behavioural changes.
"Aniracetam enhances cortical dopamine and serotonin release via cholinergic and glutamatergic mechanisms in SHRSP
Shirane M, Nakamura K.
CNS Supporting Laboratory,
Nippon Roche Research Center,
200 Kajiwara, 247-8530, Kamakura, Japan
Brain Res 2001 Oct 19;916(1-2):211-21
Abstract
Aniracetam, a cognition enhancer, has been recently found to preferentially increase extracellular levels of dopamine (DA) and serotonin (5-HT) in the prefrontal cortex (PFC), basolateral amygdala and dorsal hippocampus of the mesocorticolimbic system in stroke-prone spontaneously hypertensive rats. In the present study, we aimed to identify actually active substances among aniracetam and its major metabolites and to clarify the mode of action in DA and 5-HT release in the PFC. Local perfusion of mecamylamine, a nicotinic acetylcholine (nACh) and N-methyl-D-aspartate (NMDA) receptor antagonist, into the ventral tegmental area (VTA) and dorsal raphe nucleus (DRN) completely blocked DA and 5-HT release, respectively, in the PFC elicited by orally administered aniracetam. The effects of aniracetam were mimicked by local perfusion of N-anisoyl–aminobutyric acid (N-anisoyl-GABA), one of the major metabolites of aniracetam, into the VTA and DRN. The cortical DA release induced by N-anisoyl-GABA applied to the VTA was also completely abolished by co-perfusion of mecamylamine. Additionally, when p-anisic acid, another metabolite of aniracetam, and N-anisoyl-GABA were locally perfused into the PFC, they induced DA and 5-HT release in the same region, respectively. These results indicate that aniracetam enhances DA and 5-HT release by mainly mediating the action of N-anisoyl-GABA that targets not only somatodendritic nACh and NMDA receptors but also presynaptic nACh receptors."
[/quote]
What a wonderful rationale…thankyou so much for posting this!
Any information on whether other racetams could act in this manner? I am specifically interested in piracetam. My fear is that I won’t be able to use any of them as I’ve read pira and ani have almost the same effects just that ani seems to be more powerful on a per unit dosage.
In the end though, the only way to really know is to try it as I plan to and report back here. I’m still going to continue my experiment with ani + DMAE to see if that possibly improves things…however the mechanism above would indicate things could get worse. I gotta try it though.